Scilex Holding Company announces
completion of commercial manufacturing of Gloperba® with the brand
marketed and distributed under Scilex Pharmaceuticals, Inc. and is
expecting to Launch in the U.S. in the first quarter of 2024
Gloperba® is the first and
only liquid oral version of the anti-gout medicine colchicine indicated
for the prophylaxis of painful gout flares in adults.
Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1.
As gout cases increase every year, treatment requirements increase. The
gout treatment market is projected to be $2.0 billion in the U.S. by
2028 with a well-defined area of unmet need.2
Scilex is well-positioned to market and distribute Gloperba®:
Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S.
has an experienced commercial and managed care team that has
successfully launched and grown market access for ZTlido® (lidocaine
topical system) to more than 225 million covered lives in the U.S. as
well as successfully launching Elyxyb® (celecoxib oral solution) in the
U.S. in April 2023, the only FDA-approved ready-to-use oral solution for
the acute treatment of migraine, with or without aura, in adults.
ALTO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company
(Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating
company focused on acquiring, developing and commercializing non-opioid
pain management products for the treatment of acute and chronic pain,
today announced that it has completed commercial manufacturing of
Gloperba®, an FDA-approved prophylactic treatment for painful gout
flares in adults, in the U.S. and is expecting to launch Gloperba® in
the U.S. in the first quarter of 2024.
Gloperba® is a highly
complementary commercial asset that allows the Company to provide
physicians with another tool in their non-opioid pain management
armamentarium to treat gout earlier in the patient journey as the
Company continues to work towards re-defining the role of opioids as a
last resort rescue medication.